Transitioning From Parenteral Prostanoids to Oral Selexipag in Pulmonary Arterial Hypertension: A Multicenter Retrospective Cohort Study

ABSTRACT Transition from parenteral prostanoids to oral selexipag may be considered in select patients with pulmonary arterial hypertension (PAH) to reduce the therapeutic burden imposed on patients and caregivers, but its safety and efficacy remain uncertain. A retrospective cohort study was conduc...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Brandon Budhram, Sarah K. Alrasheed, Moaaz Rashad, George Chandy, Anna Dvorkin‐Gheva, George A. Fox, Julia Foxall, Andrea Gardner, Doug Helmersen, Naushad Hirani, Kristina Kemp, Mithum Kularatne, David Langleben, Lyda Lesenko, Steeve Provencher, Emma Spence, John R. Swiston, Mitesh Thakrar, Daniel Wadden, Jason Weatherald, Nathan Hambly
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2025-10-01
Edice:	Pulmonary Circulation
Témata:	prostacyclin pathway agents REVEAL 2.0 risk stratification therapeutic de‐escalation
On-line přístup:	https://doi.org/10.1002/pul2.70220
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!